近日，新时空研究院发布《2025年港股IPO市场年度报告》。《报告》显示，香港新股市场全年募资总额约2850亿港元，重登全球融资榜首。但这份亮眼成 绩单背后，市场结构性分化达到前所未有的程度——募资额TOP20占据全年75%的份额，近三成新股上市首日破发，流动性与认购热度向头部标的极致集 中。 募资集中度：TOP20拿走75%，A+H巨头主导格局 图片来源：新时空《2025年港股IPO市场年度报告》封面 2025年港股IPO市场募资分布呈现显著的头部集中效应。全年超110宗项目合计募资约2850亿港元，其中募资额排名前20的公司合计占全年总额的75%。"募 资王"宁德时代以356.57亿港元遥遥领先，紫金黄金国际（249.84亿港元）与赛力斯（142.83亿港元）紧随其后。 A+H公司构成募资核心力量。在募资TOP20中，A+H公司占据10席，宁德时代、赛力斯、三一重工三家巨头合计募资633.9亿港元，占全年总额的22.2%。这 些已在A股上市的制造业与消费业龙头，赴港主要动因在于搭建国际资本平台与品牌全球化。 相比之下，18A生物科技公司呈现"数量多、规模小"特征。该板块最大募资额未超20亿港元，劲方医药- ...

Core Viewpoint - The report highlights the current AH premium rates of various stocks, indicating significant disparities between H-shares and A-shares, with some stocks showing extremely high premiums while others exhibit negative premiums [1][2]. Group 1: Top AH Premium Rates - Northeast Electric (00042) leads with an AH premium rate of 815.25%, followed by Zhejiang Shibao (01057) at 363.71% and Beijing Jingcheng Machinery Electric (00187) at 272.95% [1][2]. - The top ten stocks with the highest AH premium rates include Sinopec Oilfield Service (01033) at 270.11% and Hongye Futures (03678) at 263.50% [2]. Group 2: Lowest AH Premium Rates - The stocks with the lowest AH premium rates include CATL (03750) at -11.21%, followed by Hengrui Medicine (01276) at -2.51% and China Merchants Bank (03968) at -1.68% [1][2]. - Other notable stocks with low premiums include WuXi AppTec (02359) at 2.25% and Midea Group (00300) at 7.52% [2]. Group 3: Premium Deviation Values - The stocks with the highest deviation values include Goldwind Technology (02208) at 30.93%, followed by Andeli Juice (02218) at 22.80% and CanSino Biologics (06185) at 21.10% [1][2]. - Conversely, the stocks with the lowest deviation values include Yangtze Optical Fibre and Cable (06869) at -26.96%, Nanhua Futures (02691) at -26.55%, and Northeast Electric (00042) at -26.34% [1][3].

Group 1 - The vaccine sector is experiencing a strong performance, with the medical ETF (159929) gaining 0.43% in the afternoon and surpassing a trading volume of 1.2 billion yuan, exceeding last Friday's total [1][3] - The medical ETF's constituent stocks are mostly in the green, with notable gains in vaccine stocks: Zhifei Biological up over 14%, Watson Bio up over 10%, and Hualan Biological up over 6% [3] - The top ten weighted stocks in the medical ETF account for 42.97% of the index, indicating a concentrated investment in key players within the pharmaceutical sector [7][8] Group 2 - Hualan Biological's subsidiary has received approval for clinical trials of its shingles vaccine, marking a significant breakthrough in its pipeline for preventive medicine, with expectations of increased demand due to an aging population [5] - Yiling Pharmaceutical forecasts a net profit of 1.2 to 1.3 billion yuan for 2025, indicating a turnaround from previous losses and signaling a critical operational inflection point [5] - The development of therapeutic cancer vaccines is entering a breakthrough phase, with mRNA technology leading the shift towards efficient and personalized immunotherapy, offering advantages in production, clinical safety, and strategic flexibility [6]

截至2026年1月26日 13:16，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，华兰生物领涨 5.00%，英科医疗上涨2.54%，华润三九上涨1.16%；南微医学领跌。医疗创新ETF(516820)下跌最新报 价0.37元。 生物医药概念午后快速拉升，消息面上，1月下旬，印度西孟加拉邦突发尼帕病毒疫情，已造成多名医 护人员感染，泰国、尼泊尔紧急升级防控。 数据显示，截至2025年12月31日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、恒瑞医药、迈瑞医疗、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.75%。 从资金净流入方面来看，医疗创新ETF近6天获得连续资金净流入，最高单日获得4053.70万元净流入， 合计"吸金"8499.86万元，日均净流入达1416.64万元。（数据来源：Wind） 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 26, 2026 [1] Core Insights - The report emphasizes the importance of supply-side variables, particularly the operating rates of raw material drugs, and highlights the potential for price recovery in the antibiotic market due to changes in competition and supply dynamics [2] - Multi-departmental policy support is enhancing the value positioning of pharmacies, transforming them from mere sales points to comprehensive health service platforms [3] - The trend of Chinese innovative drugs going global is gaining momentum, with significant licensing deals and the need for continuous clinical data validation to support long-term investment confidence [4] - Major companies are increasingly investing in the small nucleic acid field, which is expected to accelerate the development of the supporting industrial chain [5] - A new pricing system for GLP-1 drugs is forming in China, with expectations for market growth driven by a large patient population [6] - The report highlights the market value of oral autoimmune drugs, with promising clinical trial results for new treatments [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.23 percentage points in the last week, ranking 27th among 31 sectors [20] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector index increased by 4.98% over the past month, outperforming the CSI 300 index by 3.21 percentage points [37] - The current PE (TTM) for the pharmaceutical sector is 38.51, above the five-year historical average of 31.06 [43] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of the blood products industry and the impact of policies on inhalation formulations [45] 4. Recent Industry Policies and News - Recent policies include the approval of numerous medical device registrations and the promotion of high-quality development in the pharmaceutical retail sector [46][48]

期 货 研 究 2026 年 01 月 26 日 对二甲苯：单边趋势偏强 PTA：单边趋势偏强 MEG：单边趋势偏强 贺晓勤 投资咨询从业资格号：Z0017709 hexiaoqin@gtht.com 来源：CCF，同花顺 iFinD，S&P Global，国泰君安期货研究 PX：23 日尾盘石脑油价格仍然僵持，2 月 MOPJ 目前估价在 561 美元/吨 CFR 附近；PX 价格上涨，一 单 3 月现货在 921 成交，尾盘 3 月在 919/928 商谈，4 月在 925/942 商谈，3/4 在-6/0 商谈，1 月 23 日 PX 收 在 923 美元/吨 CFR，较昨日上涨 16 美元/吨。1 月 23 日市场现货商谈尚可，浮动价格 3 月在-6 附近有成交， 4 月在-3~-4 附近成交商谈。 Platts 公司于 1 月 23 日评估亚洲对二甲苯 CFR Unv1/中国和 FOB 韩国标志分别为 922.67 美元/公吨和 901.67 美元/吨，均较日上涨 16 美元/吨。 Platts 的数据显示，这些价格是自 2024 年 10 月 7 日以来的最高水平，当时评估价为每吨 928 美元。 ...

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [29]. Core Insights - The MSCI China Healthcare Index has increased by 9.2% since the beginning of 2026, outperforming the MSCI China Index, which rose by 5.6% [1]. - The pharmaceutical industry has seen significant growth, driven by strong institutional investor interest and the ongoing trend of innovative drugs going global [1]. - The report emphasizes the importance of clinical progress and data validation for pipelines that have already gone overseas, suggesting that this trend will continue in the long term [1]. Summary by Sections Industry Overview - The report highlights a robust trend in the outbound licensing of innovative drugs, with multiple business development (BD) transactions occurring at the start of 2026, reflecting a high level of activity in the sector [4]. - Key transactions include significant upfront and milestone payments for various drugs, indicating strong market interest and potential for future growth [4]. Company Ratings and Valuations - The report provides detailed valuations for several companies, including: - **Sangfor Technologies (1530 HK)**: Market cap of $7,598.4 million, target price of $37.58, with a 54% upside potential [2]. - **Gusongtang (2273 HK)**: Market cap of $963.3 million, target price of $44.95, with a 46% upside potential [2]. - **WuXi AppTec (2268 HK)**: Market cap of $10,551.0 million, target price of $88.00, with a 28% upside potential [2]. - **China National Pharmaceutical Group (1177 HK)**: Market cap of $15,951.4 million, target price of $9.40, with a 42% upside potential [2]. Market Trends - The report notes that the competition in the PD-(L)1/VEGF space is intensifying, with several companies advancing their clinical trials and aiming for first-line indications [4]. - The report suggests that the efficiency and breadth of clinical trials, as well as the richness of combination therapies, will be critical factors in determining success in this competitive landscape [4].

Group 1: Market Overview - A-share market showed signs of overheating, with a cumulative increase of over 10% in just 17 trading days from December 17, 2025, to January 12, 2026[8] - From January 15 to January 23, 2026, approximately 12 ETFs heavily held by the Central Huijin experienced significant outflows totaling 5590.87 billion yuan, averaging nearly 800 billion yuan per trading day[11] - The outflow was primarily from the CSI 300 (59%) and CSI 1000 indices (16%), while the STAR 50 and ChiNext saw relatively smaller outflows[13] Group 2: ETF Holdings and Impact - Central Huijin's total holdings in 23 major ETFs were approximately 1.28 trillion yuan as of mid-2025, with 12 ETFs having over 70% held by Huijin[21] - The outflow from the 13 ETFs during the specified period resulted in a share decline of approximately 13% to 54%, with the CSI 1000 ETFs experiencing the most significant drop of over 40%[21] - In extreme scenarios, the outflow could represent about 34.59% of Huijin's original holdings, leaving a remaining position of approximately 950 billion yuan[22] Group 3: Market Sentiment and Structure - Despite the outflows, market sentiment remained relatively warm, with no significant risk aversion observed, as trading activity and thematic trading remained active[25] - The market structure showed a shift towards smaller-cap stocks, with micro and small-cap indices performing strongly during the ETF redemption period[29] - Value stocks faced significant pressure, particularly in the CSI 50 index, which was impacted by simultaneous redemptions from both the CSI 300 and CSI 50 ETFs[35]

Group 1 - The core viewpoint of the news highlights the performance of the medical innovation sector, with the China Securities Medical and Medical Device Innovation Index showing mixed results among its constituent stocks, led by Hualan Biological at a 0.90% increase [1] - The Medical Innovation ETF has seen continuous net inflows over the past six days, with a peak single-day net inflow of 40.54 million yuan, totaling 84.99 million yuan and an average daily net inflow of 14.17 million yuan [1] - Central China Television announced that Galaxy General Robotics will be the designated humanoid robot for the 2026 Spring Festival Gala, marking a significant milestone for the company established in May 2023, which focuses on a wide range of applications including retail, industrial, medical, and cultural tourism [1] Group 2 - The China Securities Medical and Medical Device Innovation Index consists of 30 publicly listed companies with strong profitability, growth potential, and research innovation capabilities, reflecting the overall performance of the medical and medical device sector [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Hengrui Medicine, Mindray Medical, and others, collectively accounting for 63.75% of the index [2] Group 3 - The current medical device sector is at a turning point, with performance recovery expected in 2026, driven by new technologies such as AI in healthcare, brain-machine interfaces, and surgical robots, leading to a continuous revaluation of innovative products with global competitiveness [1]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the potential acceleration of the surgical robot industry following the release of the service pricing guidelines by the National Medical Insurance Administration, which clarifies the pricing structure for surgical robot services and consumables [3][18] - The report emphasizes the importance of innovation in the pharmaceutical sector, noting that the industry has completed a transition from old to new growth drivers, particularly in innovative drugs, which are expected to continue to perform well in 2026 [46][47] - The report suggests a focus on sectors such as innovative drugs, AI medical technology, and brain-computer interfaces, which are anticipated to see significant advancements in 2026 [46][48] Summary by Sections Market Performance - From January 19 to January 23, the pharmaceutical index decreased by 0.39%, with an excess return of 0.23% relative to the CSI 300 index. The market was relatively stable, with a notable increase of 1.26% on Friday, driven by themes like brain-computer interfaces and AI medical technology [5][27] - A total of 330 stocks rose while 137 fell during the week, with notable gainers including *ST Changyao (+70.37%) and Hualan Biological (+32.21%) [27][28] Surgical Robot Industry - The surgical robot market is expected to benefit from the new pricing guidelines, which will enhance the clinical application of surgical robots and promote a sustainable business model [3][18] - The domestic laparoscopic robot market is projected to grow significantly, with a compound annual growth rate (CAGR) of 29.3% from 2024 to 2030 [9][15] Investment Recommendations - The report recommends focusing on strong fundamentals and well-adjusted innovative drug stocks, including companies like Xinlitai, Zexing Pharmaceutical, and Hengrui Medicine, as well as medical technology firms like Yuyue Medical and Alibaba Health [5][49] - It also suggests monitoring companies involved in the export of CXO services and those with stable operations and low valuations that are expected to see fundamental changes in 2026 [5][46] Future Outlook - The report anticipates that the pharmaceutical industry will continue to improve marginally in 2026, driven by technological innovation and performance recovery in traditional sectors [46][47] - Key areas of focus include innovative drugs, AI medical technology, and the aging population's healthcare needs, which are expected to drive demand [46][48]